GlaxoSmithKline's shingles shot scores in 16,000-patient study

GlaxoSmithKline ($GSK) is one step closer to challenging Merck's ($MRK) Zostavax vaccine. Glaxo rolled out data from a hefty Phase III study showing that its shingles-fighting candidate cut the risk of that disease by 97.2% in adults aged 50 and older, compared with placebo. Report